Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. Rarebase appears in 1 tracked Biotech story from March 22, 2026. The tracked stories average 3 original sources each.
Last mentioned: Mar 22, 2026
Entity pulse
Coverage balance Positive coverage leads. Positive coverage exceeds negative coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention FDA, the most common co-covered peer. Rarebase appears in 1 tracked Biotech story from March 22, 2026. The tracked stories average 3 original sources each.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 10 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Rarebase. Shared-story counts are live from our verified record — not editorial picks.
Rarebase is pioneering a high-throughput drug discovery model that screens existing FDA-approved medications against thousands of rare genetic disorders. By partnering directly with patient advocacy groups, the lab aims to bypass traditional R&D hurdles and find immediate treatments for 'orphan' conditions.
Rarebase is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
